macrophage, cancer biology, CAR, chimeric antigen receptor, CAR T cells, solid cancer, tumor, liquid cancer, immunotherapy, immunology, disease & medicine, techniques
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

  1. Home
  2. Subjects
  3. solid cancer
solid cancer
Finding CAR T Cells in Solid Tumors by Single-Cell Resolution
Finding CAR T Cells in Solid Tumors at Single-Cell Resolution
The Scientist Creative Services Team in collaboration with Miltenyi Biotec | Nov 12, 2021
Rita Pfeifer will discuss visualizing and quantifying CAR T-cell infiltration into solid tumors with 3-D light sheet fluorescence microscopy (LSFM).
Discover How to Accelerate and Improve CAR-T therapy development
Advances in Solid Tumor Immunotherapies
Sartorius | Oct 6, 2021
By screening for novel tumor targets, researchers build better CAR-T cell therapies.
Enhancing the Efficacy of CAR-T Cell Therapies
The Scientist Creative Services Team in Collaboration with IsoPlexis | Jun 29, 2021
Jessica Morris will discuss strategies to improve CAR-T cell targeting, activation, and killing capabilities.
cancer blood hematologic leukemia solid tumor covid-19 sars-cov-2 coronavirus pandemic mortality t cell b cd8+ cd4+ immunology chemotherapy
COVID-19 More Deadly with Blood than Solid Cancer: Study
Marcus A. Banks | Feb 16, 2021
Death rates among blood cancer patients who contract COVID-19 are higher than for those with other cancers, pointing to impaired immunity that makes it hard to overcome the virus.
CAR T cells, oncolytic virus, CD19, mouse model, solid cancer, liquid cancer, tumor, immune response, immunotherapy, T cell, treatment
Immunotherapy Combo Reduces Solid Tumors in Mice
Amanda Heidt | Sep 9, 2020
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.